Tanium Converge Travels to London and Paris
13.4.2023 10:00:00 EEST | Business Wire | Press release
Tanium, the industry’s only provider of converged endpoint management (XEM), today announced the beginning of the Converge World Tour 2023, a six-city series of its global user conference. The kickoff event in London will be held Tuesday, 18th April, at the London Landmark Hotel, with a show at the Campus Cyber, Paris to follow on Thursday where Tanium will showcase its innovation spotlight, including its product roadmap and future enhancements to the XEM platform.
Converge is Tanium’s flagship event that brings together industry specialists, peers, and partners to share strategies for leveraging converged endpoint management (XEM) to improve organizational cybersecurity readiness and response. There’s no better opportunity for IT and security practitioners to discover new ways of driving value to their boards and accelerating business initiatives than to gain outside perspectives and hear first-hand experiences from those on the frontline of the cyber landscape.
“Tanium’s commitment is first, last, and always to our customers, and we are grateful to have such a strong and extensive partner ecosystem that is equally committed to maximizing the value our customers achieve from their investments in Tanium,” said Steve Daheb, chief marketing officer at Tanium. “Join us in Paris and London to see why Forrester reports Tanium driving ROI of more than 200% for customers, why eight of top 10 global financial institutions and seven of the top 10 global retailers trust Tanium to maximize their ROI and simplify their technology environments while defending their organizations against emerging threats and expanding their knowledge of managing risk, securing technology, and unlocking innovation at scale from a single intuitive platform.”
Join Tanium for a dynamic keynote experience, featuring top executives and industry experts who will enable you to:
- Glimpse into the future with Tanium—including the global unveiling of a new offering designed to improve overall work productivity, increase employee satisfaction, and lower IT support costs
- Understand the use and benefits of XEM with category creator Steve Daheb
- Gain insights from an intimate fireside chat with customer success champion Charles Ross
- Explore the many ways Microsoft and Tanium work better together to improve cyber resilience with partner facilitator Mike Fiorina
- Get a firsthand look at real customer successes with a panel featuring Aviva and Fraser’s Group and partner enablement executive Todd Palmer
- Participate in peer-based breakout sessions across executive-, technical-, and partner-focused tracks
WHO : IT and security professionals from across Europe; Tanium’s newly appointed CEO, Dan Streetman, and members of his executive team; Forrester analyst Andrew Hewitt; Frasers Group’s Matthew Wilmot; Aviva’s Marc Hasketh-Boston; and Tanium customers and partners that include EY, PwC, Armadillo Managed Services, Computacenter, SCC, EndpointX, Pointwire, BlueTrusty, Capgemini, Cegedim, DOUNYX, EY, I-TRACING, Orange Cyberdefense, and more
WHAT : Tanium Converge London and Tanium Converge Paris, featuring spotlights on current trends, industry best practices, expert-led sessions, breakout discussions, and hands-on labs
WHER E: The Landmark London Hotel and the Campus Cyber in Paris–La Defense
WHEN : Tuesday, 18th April 2023 (London) and Thursday, 20th April (Paris)
HOW : The shows are sold out, but you can still register to secure your place on the waitlist or join us for mainstage public sessions on demand by signing up for the London show or the Paris event. We look forward to seeing you there!
About Tanium
Tanium, the industry’s only provider of converged endpoint management (XEM), is the reference platform of choice to manage complex security and technology environments. Only Tanium unifies teams and workflows and protects every endpoint from cyber threats by integrating IT, Compliance, Security, and Risk into a single platform that delivers comprehensive visibility across devices, a unified set of controls, and a common taxonomy for a single shared purpose: to protect critical information and infrastructure at scale. Tanium has been named to the Forbes Cloud 100 list for seven consecutive years and ranks on Fortune’s list of the Best Large Workplaces in Technology. In fact, more than half of the Fortune 100 and the U.S. armed forces trust Tanium to protect people; defend data; secure systems; and see and control every endpoint, team, and workflow everywhere. That’s the power of certainty. Visit www.tanium.com and follow us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005318/en/
Contact information
Lindsey Lockhart
Tanium PR
press@tanium.com
+ 1 214.562.1521
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom